{"id":72438,"date":"2026-08-13T12:30:23","date_gmt":"2026-08-13T04:30:23","guid":{"rendered":"https:\/\/flcube.com\/?p=72438"},"modified":"2026-08-13T12:30:24","modified_gmt":"2026-08-13T04:30:24","slug":"astrazeneca-and-daiichi-sankyos-enhertu-wins-china-approval-for-first-line-her2-positive-metastatic-breast-cancer-in-combination-with-pertuzumab","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72438","title":{"rendered":"AstraZeneca and Daiichi Sankyo&#8217;s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) and <strong>Daiichi Sankyo<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4568:TYO\">TYO: 4568<\/a>) announced that a new indication for <strong>Enhertu (trastuzumab deruxtecan for injection)<\/strong> has been <strong>approved in China<\/strong> \u2014 for use <strong>in combination with pertuzumab<\/strong> in the <strong>first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer<\/strong>, extending the blockbuster ADC into the earliest treatment setting in the world&#8217;s second-largest pharmaceutical market.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>AstraZeneca plc (NYSE: AZN) \u00d7 Daiichi Sankyo (TYO: 4568)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Enhertu (trastuzumab deruxtecan for injection)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>New indication approval in China<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, in combination with pertuzumab<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>12 Aug 2026<\/td><\/tr><tr><td><strong>Supporting Trial<\/strong><\/td><td>Phase III DESTINY-Breast09<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-trastuzumab-deruxtecan\" class=\"wp-block-heading\">Drug Profile \u2013 Trastuzumab Deruxtecan<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> <strong>HER2-directed antibody-drug conjugate (ADC)<\/strong><\/li>\n\n\n\n<li><strong>Platform:<\/strong> Designed using <strong>Daiichi Sankyo&#8217;s proprietary DXd ADC technology<\/strong><\/li>\n\n\n\n<li><strong>Development:<\/strong> Designed by Daiichi Sankyo; <strong>jointly developed and commercialized<\/strong> by Daiichi Sankyo and AstraZeneca<\/li>\n\n\n\n<li><strong>Strategic Position:<\/strong> One of oncology&#8217;s highest-selling ADCs, now advancing from later-line use into first-line HER2-positive breast cancer<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-destiny-breast09-phase-iii\" class=\"wp-block-heading\">Clinical Evidence \u2013 DESTINY-Breast09 (Phase III)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>T-DXd + Pertuzumab<\/th><th>THP (Taxane + Trastuzumab + Pertuzumab)<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Risk of Progression or Death<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td><strong>44% risk reduction<\/strong><\/td><\/tr><tr><td><strong>Hazard Ratio (HR)<\/strong><\/td><td>0.56 (95% CI: 0.44\u20130.71)<\/td><td>Reference<\/td><td><strong>p &lt; 0.00001<\/strong><\/td><\/tr><tr><td><strong>Median PFS (BICR)<\/strong><\/td><td><strong>40.7 months<\/strong> (95% CI: 36.5\u2013NE)<\/td><td>26.9 months (95% CI: 21.8\u2013NE)<\/td><td><strong>+13.8 months<\/strong><\/td><\/tr><tr><td><strong>Subgroup Consistency<\/strong><\/td><td>Consistent PFS improvements across prespecified subgroups; China subgroup consistent with global population<\/td><td>\u2013<\/td><td>Broad applicability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Population:<\/strong> Patients with HER2-positive metastatic breast cancer who had received <strong>no prior chemotherapy or HER2-targeted therapy<\/strong> for advanced disease, or who had completed neoadjuvant\/adjuvant HER2-targeted therapy <strong>more than six months<\/strong> before diagnosis of advanced or metastatic disease<\/li>\n\n\n\n<li><strong>Assessment:<\/strong> Progression-free survival assessed by <strong>blinded independent central review (BICR)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Standard of Care Shift:<\/strong> A 44% reduction in progression-or-death risk against the entrenched THP regimen establishes a compelling new first-line option and pressures the long-standing taxane backbone standard.<\/li>\n\n\n\n<li><strong>China Commercial Significance:<\/strong> China carries one of the world&#8217;s largest HER2-positive breast cancer populations; first-line approval materially expands Enhertu&#8217;s addressable market in the region.<\/li>\n\n\n\n<li><strong>ADC Franchise Momentum:<\/strong> The approval extends the Enhertu franchise into earlier lines of therapy, a pattern driving the ADC&#8217;s global uptake and supporting the Daiichi Sankyo\u2013AstraZeneca alliance as one of oncology&#8217;s most commercially consequential partnerships.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Pricing, reimbursement access, and launch timelines in China were not disclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the commercialization and clinical potential of Enhertu in China. Actual results may differ due to risks including reimbursement outcomes, market adoption, safety monitoring, and competitive dynamics in HER2-targeted oncology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,130,16,194,4621,15,978],"class_list":["post-72438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-astrazeneca","tag-cancer","tag-daiichi-sankyo","tag-nyse-azn","tag-product-approvals","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca and Daiichi Sankyo&#039;s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for Enhertu (trastuzumab deruxtecan for injection) has been approved in China \u2014 for use in combination with pertuzumab in the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, extending the blockbuster ADC into the earliest treatment setting in the world&#039;s second-largest pharmaceutical market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72438\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca and Daiichi Sankyo&#039;s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for Enhertu (trastuzumab deruxtecan for injection) has been approved in China \u2014 for use in combination with pertuzumab in the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, extending the blockbuster ADC into the earliest treatment setting in the world&#039;s second-largest pharmaceutical market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72438\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T04:30:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T04:30:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca and Daiichi Sankyo&#8217;s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab\",\"datePublished\":\"2026-08-13T04:30:23+00:00\",\"dateModified\":\"2026-08-13T04:30:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1301.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"Cancer\",\"Daiichi Sankyo\",\"NYSE:\u202fAZN\",\"Product approvals\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72438#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72438\",\"name\":\"AstraZeneca and Daiichi Sankyo's Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1301.webp\",\"datePublished\":\"2026-08-13T04:30:23+00:00\",\"dateModified\":\"2026-08-13T04:30:24+00:00\",\"description\":\"AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for Enhertu (trastuzumab deruxtecan for injection) has been approved in China \u2014 for use in combination with pertuzumab in the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, extending the blockbuster ADC into the earliest treatment setting in the world's second-largest pharmaceutical market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72438\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1301.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca and Daiichi Sankyo's Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72438#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca and Daiichi Sankyo&#8217;s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca and Daiichi Sankyo's Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for Enhertu (trastuzumab deruxtecan for injection) has been approved in China \u2014 for use in combination with pertuzumab in the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, extending the blockbuster ADC into the earliest treatment setting in the world's second-largest pharmaceutical market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72438","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca and Daiichi Sankyo's Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab","og_description":"AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for Enhertu (trastuzumab deruxtecan for injection) has been approved in China \u2014 for use in combination with pertuzumab in the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, extending the blockbuster ADC into the earliest treatment setting in the world's second-largest pharmaceutical market.","og_url":"https:\/\/flcube.com\/?p=72438","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-13T04:30:23+00:00","article_modified_time":"2026-08-13T04:30:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72438#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72438"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca and Daiichi Sankyo&#8217;s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab","datePublished":"2026-08-13T04:30:23+00:00","dateModified":"2026-08-13T04:30:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72438"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72438#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1301.webp","keywords":["ADC \/ XDC","AstraZeneca","Cancer","Daiichi Sankyo","NYSE:\u202fAZN","Product approvals","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72438#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72438","url":"https:\/\/flcube.com\/?p=72438","name":"AstraZeneca and Daiichi Sankyo's Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72438#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72438#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1301.webp","datePublished":"2026-08-13T04:30:23+00:00","dateModified":"2026-08-13T04:30:24+00:00","description":"AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for Enhertu (trastuzumab deruxtecan for injection) has been approved in China \u2014 for use in combination with pertuzumab in the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, extending the blockbuster ADC into the earliest treatment setting in the world's second-largest pharmaceutical market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72438#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72438"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72438#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1301.webp","width":1080,"height":608,"caption":"AstraZeneca and Daiichi Sankyo's Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72438#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca and Daiichi Sankyo&#8217;s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1301.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72438"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72438\/revisions"}],"predecessor-version":[{"id":72440,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72438\/revisions\/72440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72439"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}